Entia non sunt multiplicanda praeter necessitate.
William of Ockham (c. 1285-1349), author of the Ockham’s Razor principle.
OCKHAM BIOTECH LIMITED
The compelling science and a remarkable opportunity
Welcome to Ockham Biotech. We are a research company focussed on the development of inhaled heparin for the treatment of obstructive airway diseases, including cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), asthma and non-CF bronchiectasis (NCFBE).
We are currently seeking partners for the commercialisation of inhaled heparin derivatives in CF, COPD, bronchiectasis, asthma and other diseases characterised by airway obstruction with mucus.
Our work on the use of heparin and its derivatives for respiratory diseases and epidemiology presents a remarkable opportunity for prospective partners. Please read more about the research and development, clinical trials and patents that underpin this compelling science and the attractive commercial prospects that should appeal to investors who appreciate its significance.
If you would like to know more about our work or to talk to us about investment opportunities, please contact us.